Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A Clinical Trial

Official title:
Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Status Completed

Clinical Trial Summary

The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of bleeding episodes in real-life clinical practice in Europe and the United States.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03199794
Study type	Observational
Source	Takeda
Contact
Status	Completed
Phase
Start date	December 14, 2016
Completion date	July 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03700229` - Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A	Phase 2
Completed	`NCT04580407` - Study of TAK-672 in Participants With Acquired Hemophilia A	Phase 2/Phase 3
Completed	`NCT01178294` - Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A	Phase 2/Phase 3
Recruiting	`NCT06461533` - A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
Completed	`NCT02610127` - Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Completed	`NCT03384277` - Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab	Phase 4
Recruiting	`NCT05345197` - Emicizumab in Patients With Acquired Hemophilia A	Phase 2
No longer available	`NCT01968655` - Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies